The use of SBRT in the management of oligometastatic gynecological cancer: report of promising results in terms of tolerability and clinical outcomes.
Gynecological malignancies
Oligometastases
Stereotactic body radiotherapy
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
12
08
2021
accepted:
12
09
2021
pubmed:
22
9
2021
medline:
6
11
2021
entrez:
21
9
2021
Statut:
ppublish
Résumé
The use of stereotactic radiotherapy (SBRT) for oligometastases is supported by several literature studies, but in the setting of gynecological malignancies, this scenario remains quite unexplored. This study reports a preliminary assessment of clinical outcomes in a cohort of 40 patients with oligometastatic gynecological neoplasms. Radiotherapy was delivered in 3-10 fractions with VMAT-IGRT technique. Toxicity was retrospectively collected according to CTCAE v4.0. Data were retrospectively collected and analyzed. Univariate and multivariate analyses were performed for assessing any potential predictive factor for clinical outcomes. A total of 63 oligometastases were treated from December 2014 to February 2021. Median age was 63 years (range 30-89). Most frequent primary tumors were ovarian cancer in 42.5% and endometrium cancer in 42.5%. With a median follow-up of 27 months (range 6-69), no local failures were observed, our progression-free survival rates were 43.6% and 23% at one and 2 years, respectively, while 1 and 2-year overall survival rates were both 70%. No acute or late G ≥ 2 adverse events were observed. In our experience, SBRT for oligometastatic gynecological malignancies resulted in promising results in terms of clinical outcomes, with excellent local control and no evidence of severe toxicity, highlighting the effectiveness of this therapeutic option. Prospective studies to further explore this approach in this setting are advocated.
Sections du résumé
BACKGROUND
BACKGROUND
The use of stereotactic radiotherapy (SBRT) for oligometastases is supported by several literature studies, but in the setting of gynecological malignancies, this scenario remains quite unexplored. This study reports a preliminary assessment of clinical outcomes in a cohort of 40 patients with oligometastatic gynecological neoplasms.
METHODS
METHODS
Radiotherapy was delivered in 3-10 fractions with VMAT-IGRT technique. Toxicity was retrospectively collected according to CTCAE v4.0. Data were retrospectively collected and analyzed. Univariate and multivariate analyses were performed for assessing any potential predictive factor for clinical outcomes.
RESULTS
RESULTS
A total of 63 oligometastases were treated from December 2014 to February 2021. Median age was 63 years (range 30-89). Most frequent primary tumors were ovarian cancer in 42.5% and endometrium cancer in 42.5%. With a median follow-up of 27 months (range 6-69), no local failures were observed, our progression-free survival rates were 43.6% and 23% at one and 2 years, respectively, while 1 and 2-year overall survival rates were both 70%. No acute or late G ≥ 2 adverse events were observed.
CONCLUSIONS
CONCLUSIONS
In our experience, SBRT for oligometastatic gynecological malignancies resulted in promising results in terms of clinical outcomes, with excellent local control and no evidence of severe toxicity, highlighting the effectiveness of this therapeutic option. Prospective studies to further explore this approach in this setting are advocated.
Identifiants
pubmed: 34545423
doi: 10.1007/s00432-021-03802-4
pii: 10.1007/s00432-021-03802-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3613-3618Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Buechel M, Herzog TJ, Westin SN et al (2019) Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol 30:721–732
doi: 10.1093/annonc/mdz104
Camara H, Zhang Y, Lafferty L, Vallely AJ, Guy R, Kelly-Hanku A (2021) Self-collection for HPV-based cervical screening: a qualitative evidence meta-synthesis. BMC Public Health 21(1):1503. https://doi.org/10.1186/s12889-021-11554-6
doi: 10.1186/s12889-021-11554-6
pubmed: 34348689
pmcid: 8336264
Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry L, Webster G, Ostler P, Dickinson PD, Hatton MQ, Henry A, Keevil S, Hawkins MA, Slevin N, van As N (2021) Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol 22(1):98–106. https://doi.org/10.1016/S1470-2045(20)30537-4
doi: 10.1016/S1470-2045(20)30537-4
pubmed: 33387498
Cronin KA, Lake AJ, Scott S et al (2018) Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 124:2785–2800
doi: 10.1002/cncr.31551
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21(1):e18–e28
doi: 10.1016/S1470-2045(19)30718-1
Hanna GG, Murray L, Patel R et al (2018) UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol 30(1):5–14 (ISSN 0936-6555)
doi: 10.1016/j.clon.2017.09.007
Iftode C, DAgostino GR, Tozzi A, Comito T, Franzese C, De Rose F, Franceschini D, Di Brina L, Tomatis S, Scorsetti M, (2018) Stereotactic body radiation therapy in oligometastatic ovarian cancer: a promising therapeutic approach. Int J Gynecol Cancer 28(8):1507–1513. https://doi.org/10.1097/IGC.0000000000001324
doi: 10.1097/IGC.0000000000001324
pubmed: 30036231
Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T et al (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol off J Am Soc Clin Oncol 33:2129–2135
doi: 10.1200/JCO.2014.58.4391
Lehrer EJ, Singh R, Wang M, Chinchilli VM, Trifiletti DM, Ost P, Siva S, Meng MB, Tchelebi L, Zaorsky NG (2021) Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol 7(1):92–106. https://doi.org/10.1001/jamaoncol.2020.6146
doi: 10.1001/jamaoncol.2020.6146
pubmed: 33237270
Ling DC, Vargo JA, Burton SA, Heron DE, Beriwal S (2019) Salvage Curative-Intent Reirradiation Stereotactic Body Radiation Therapy for Isolated Pelvic and/or Paraortic Recurrences of Gynecologic Malignancies. Pract Radiat Oncol 9(6):418–425
doi: 10.1016/j.prro.2019.05.012
Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J et al (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:4626–4633
doi: 10.1200/JCO.2005.10.021
Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, D’Agostino GR, Deodato F, Maranzano E, Ippolito E, Ronchi S, Paiar F, Scorsetti M, Cilla S, Ingargiola R, Huscher A, Cerrotta AM, Fodor A, Vicenzi L, Russo D, Borghesi S, Perrucci E, Pignata S, Aristei C, Morganti AG, Scambia G, Valentini V, Jereczek-Fossa BA, Ferrandina G (2020) A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. Oncologist 25(2):e311–e320
doi: 10.1634/theoncologist.2019-0309
Moraes FY, Chen X, Yan M et al (2020) Evolving role of stereotactic body radiation therapy in the management of spine metastases: defining dose and dose constraints. Neurosurg Clin N Am 31(2):167–189. https://doi.org/10.1016/j.nec.2019.12.001
doi: 10.1016/j.nec.2019.12.001
pubmed: 32147009
Nicosia L, Cuccia F, Mazzola R, Ricchetti F, Figlia V, Giaj-Levra N, Rigo M, Tomasini D, Pasinetti N, Corradini S, Ruggieri R, Alongi F (2020a) Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlenther Onkol 196(9):813–820. https://doi.org/10.1007/s00066-020-01627-7
doi: 10.1007/s00066-020-01627-7
pubmed: 32399637
Nicosia L, Cuccia F, Mazzola R, Figlia V, Giaj-Levra N, Ricchetti F, Rigo M, Bonù M, Corradini S, Tolia M, Alongi F (2020b) Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. J Cancer Res Clin Oncol 146(9):2351–2358. https://doi.org/10.1007/s00432-020-03223-9
doi: 10.1007/s00432-020-03223-9
pubmed: 32356176
Ning MS, Ahobila V, Jhingran A, Stecklein SR, Frumovitz M, Schmeler KM, Eifel PJ, Klopp AH (2018) Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecol Oncol 148(1):132–138. https://doi.org/10.1016/j.ygyno.2017.10.017
doi: 10.1016/j.ygyno.2017.10.017
pubmed: 29089122
Onal C, Gultekin M, Oymak E, Guler OC, Yilmaz MT, Yuce Sari S, Akkus Yildirim B, Yildiz F (2020) Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis. Int J Gynecol Cancer 30(6):865–872. https://doi.org/10.1136/ijgc-2019-001115
doi: 10.1136/ijgc-2019-001115
pubmed: 32273293
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393(10185):2051–2058
doi: 10.1016/S0140-6736(18)32487-5
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II Randomized Trial. J Clin Oncol 38(25):2830–2838. https://doi.org/10.1200/JCO.20.00818
doi: 10.1200/JCO.20.00818
pubmed: 32484754
pmcid: 7460150
Passarello K, Kurian S, Villanueva V (2019) Endometrial cancer: an overview of pathophysiology, management, and care. Semin Oncol Nurs 35(2):157–165
doi: 10.1016/j.soncn.2019.02.002
Pollom EL, Chin AL, Diehn M, Loo BW, Chang DT (2017) Normal tissue constraints for abdominal and thoracic stereotactic body radiotherapy. Semin Radiat Oncol 27(3):197–208. https://doi.org/10.1016/j.semradonc.2017.02.001
doi: 10.1016/j.semradonc.2017.02.001
pubmed: 28577827
Reddy AV, Mills MN, Reshko LB, Martin Richardson K, Kersh CR (2020) Stereotactic body radiation therapy in oligometastatic uterine cancer: clinical outcomes and toxicity. Cancer Invest 38(8–9):522–530. https://doi.org/10.1080/07357907.2020.1817483
doi: 10.1080/07357907.2020.1817483
pubmed: 32870714
Reshko LB, Baliga S, Crandley EF, Harry Lomas IV, Richardson MK, Spencer K, Bennion N, Mikdachi HE, Irvin W, Kersh CR (2020) Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers. Gynecol Oncol 159(3):611–617
doi: 10.1016/j.ygyno.2020.10.001
Sahgal A, Chang JH, Ma L, Marks LB, Milano MT, Medin P, Niemierko A, Soltys SG, Tomé WA, Wong CS, Yorke E, Grimm J, Jackson A (2019) Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys S0360–3016(19):33862–33863. https://doi.org/10.1016/j.ijrobp.2019.09.038
doi: 10.1016/j.ijrobp.2019.09.038
Smile TD, Reddy CA, Qiao-Guan G, Winter WI, Stephans KL, Woody NM, Balagamwala EH, Amarnath SR, Magnelli A, AlHilli MM, Michener CM, Mahdi H, DeBernardo RL, Rose PG, Cherian SS (2021) Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: a single-institution experience. J Radiosurg SBRT 7(3):189–197
pubmed: 33898082
Stewart C, Ralyea C, Lockwood S (2019) Ovarian cancer: an integrated review. Semin Oncol Nurs 35(2):151–156
doi: 10.1016/j.soncn.2019.02.001
Zhang TW, Palma D, D’Souza D, Velker V, Mendez LC (2020) Stereotactic ablative radiotherapy for recurrent or metastatic gynecological cancer: extending lives? Curr Treat Options Oncol 21(7):58. https://doi.org/10.1007/s11864-020-00748-6
doi: 10.1007/s11864-020-00748-6
pubmed: 32533272